Full Text
Cost-Effectiveness of Mepolizumab Versus Omalizumab as an Adjunct Therapy in Patients with Uncontrolled Allergic Asthma

Abstract

Authors

S Korgaonkar S Inguva Y Yang

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×